Imperial College London

ProfessorNicholasGrassly

Faculty of MedicineSchool of Public Health

Prof of Infectious Disease & Vaccine Epidemiology
 
 
 
//

Contact

 

n.grassly Website

 
 
//

Location

 

1102Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Shirreff:2016:10.3201/eid2302.161210,
author = {Shirreff, G and Wadood, MZ and Vaz, RG and Sutter, RW and Grassly, NC},
doi = {10.3201/eid2302.161210},
journal = {Emerging Infectious Diseases},
pages = {258--263},
title = {Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014-April 2016},
url = {http://dx.doi.org/10.3201/eid2302.161210},
volume = {23},
year = {2016}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - In 2014, inactivated poliovirus vaccine (IPV) campaigns were implemented in Nigeria and Pakistan after clinical trials showed that IPV boosts intestinal immunity in children previously given oral poliovirus vaccine (OPV). We estimated the effect of these campaigns by using surveillance data collected during January 2014–April 2016. In Nigeria, campaigns with IPV and trivalent OPV (tOPV) substantially reduced the incidence of poliomyelitis caused by circulating serotype-2 vaccine–derived poliovirus (incidence rate ratio [IRR] 0.17 for 90 days after vs. 90 days before campaigns, 95% CI 0.04–0.78) and the prevalence of virus in environmental samples (prevalence ratio [PR] 0.16, 95% CI 0.02–1.33). Campaigns with tOPV alone resulted in similar reductions (IRR 0.59, 95% CI 0.18–1.97; PR 0.45, 95% CI 0.21–0.95). In Pakistan, the effect of IPV+tOPV campaigns on wild-type poliovirus was not significant. Results suggest that administration of IPV alongside OPV can decrease poliovirus transmission if high vaccine coverage is achieved.
AU - Shirreff,G
AU - Wadood,MZ
AU - Vaz,RG
AU - Sutter,RW
AU - Grassly,NC
DO - 10.3201/eid2302.161210
EP - 263
PY - 2016///
SN - 1080-6040
SP - 258
TI - Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014-April 2016
T2 - Emerging Infectious Diseases
UR - http://dx.doi.org/10.3201/eid2302.161210
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000393088600010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - http://hdl.handle.net/10044/1/49888
VL - 23
ER -